Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) CEO Sells $15,338,011.30 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $648.70 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business’s 50 day simple moving average is $669.92 and its two-hundred day simple moving average is $668.75. The stock has a market capitalization of $51.65 billion, a P/E ratio of 49.63, a price-to-earnings-growth ratio of 3.86 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the business posted $2.53 EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Institutional Trading of IDEXX Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after acquiring an additional 86,040 shares in the last quarter. Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $3,666,459,000. State Street Corp lifted its holdings in shares of IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after purchasing an additional 138,956 shares in the last quarter. J. Stern & Co. LLP lifted its holdings in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. UBS Group dropped their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.